Pfizer (PFE) stops developing hep-C drug on strategic review - DJN
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Traders Still See Value in Pfizer (PFE) on Pullback from Annual Highs
March 8, 2013 10:40 AM ESTAmid a bout of selling today, some traders are taking the move as a buying signal for Pfizer (NYSE: PFE).
Market data points to about $22.8 million of net money flow favoring an uptick in Pfizer shares. The current uptick-to-downtick on the stock is 2.7... More
